Phase I study of single agent NIZ985, a recombinant heterodimeric IL-15 agonist, in adult patients with metastatic or unresectable solid tumors

Overview of attention for article published in Journal for Immunotherapy of Cancer, November 2021

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (87th percentile)
High Attention Score compared to outputs of the same age and source (81st percentile)

Mentioned by

twitter: 11 X users

patent: 4 patents

Readers on

mendeley: 57 Mendeley

So far, Altmetric has seen 13 X posts from 11 X users, with an upper bound of 24,170 followers.

New 3i Investigator Article Alert!! Phase I study of single agent NIZ985, a recombinant heterodimeric IL-15 agonist, in adult patients with metastatic or unresectable solid tumors https://t.co/l8UDfIBqIS #sciencetwitter #academictwitter

Phase I study of single agent NIZ985, a recombinant heterodimeric IL-15 agonist, in adult patients with metastatic or unresectable solid tumors https://t.co/dVB4XzFfEn

RT @georgepavlakis: We describe first-in-human study of hetIL-15/NIZ985,a molecule close to the natural human cytokine, responsible for the…

This page shows the most recent X posts that mention this research output. Click here to find out how to access more activity, including 9 additional X posts.